Form 4: Pfizer Executive Vice President Sally Susman Reports Stock Transactions
SEC Form 4 Filing
Sally Susman, Executive Vice President of Pfizer, reports the earn-out of stock appreciation rights and related transactions on February 23, 2024.
Summary
- On February 23, 2024, Sally Susman, Executive Vice President of Pfizer, engaged in transactions involving Pfizer common stock and stock appreciation rights.
- Susman earned out 63,837 stock appreciation rights at a price of $27.34.
- She also disposed of 4,948 shares to satisfy tax obligations at $27.76 per share.
- An additional 51,589 shares were withheld to cover the exercise price of the stock appreciation rights at $27.37 per share.
- Following these transactions, Susman directly owns 161,611 shares of Pfizer common stock and indirectly owns 813 shares through a Rule 16b-3 plan.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting standard insider trading activity. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities and beneficial ownership of company stock.
Stakeholder Impact
- The transactions reported may have a minor impact on shareholders by slightly diluting the stock.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of the reported transactions (earn-out of stock appreciation rights, tax withholding, and exercise price coverage). |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.